Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

Initializing

Gaining access to millions of annotated cells across 10+ cancer indications.

Analyzing pathology slides

Our algorithms detect and characterize tissue and cell architecture.

Calculating Features

Cell & area locations are intersected to compute over hundreds of complex feature values.

Predicting Response

Deep-learning models combining spatial features and clinical data drive the discovery of pathology based spatial biomarkers.

PRODUCTS

Our Offering

Exploratory Research Platform

Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.

AI-Powered Clinical Trial Assays

Qualified biomarkers are incorporated into prospective clinical trials via Nucleai’s AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.

Companion Diagnostics Development

In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai’s digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.

Our Platform

Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.

ABOUT US

We are transforming precision medicine with AI-powered pathology

Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.

DATA & INSTITUTIONAL PARTNERS

SCIENTIFIC PUBLICATIONS

LEADERSHIP

ADVISORS

CAREERS

Join Us in Biomarker Discovery

At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.

NEWS & UPDATES

Nucleai Raises $33M in Series B Round [GenomeWeb]

Spatial biology company Nucleai has closed a $33 million Series B financing round led jointly by Section 32 and Sanofi Ventures, the firm announced on Tuesday. Nucleai plans to use the new financing to advance its spatial analysis platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations. The company’s platform helps […]

Read More

Add Your Heading Text Here